GlassScriptPhysician profile
Murthy V Andavolu
NPI 1952350548
$4,352.38
in general payments reported to CMS, 2019-2025
42 companies · $926 in 2025
The $926 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $131 · 2021: $519 · 2022: $807 · 2023: $690 · 2024: $814 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,187 · Education: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,187.17 |
| Education | $243.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $648.81 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $378.15 | 2021-2025 | Imfinzi, Enhertu, Calquence |
| Seagen INC. | $313.10 | 2021-2023 | Adcetris |
| Beone Medicines USA, INC. | $185.82 | 2025 | Brukinsa, Tevimbra |
| Incyte Corporation | $184.54 | 2021-2025 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $181.21 | 2020-2025 | Opdivo |
| Amgen INC. | $171.62 | 2019-2022 | |
| Genentech USA, INC. | $171.31 | 2020-2025 | Venclexta, Gazyva, Polivy |
| Genzyme Corporation | $170.26 | 2020-2024 | |
| Daiichi Sankyo INC. | $147.62 | 2022-2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $147.46 | 2019-2025 | Fruzaqla, Ninlaro |
| Novo Nordisk INC | $125.00 | 2019 | |
| Glaxosmithkline, LLC. | $118.46 | 2021-2025 | Zejula, Blenrep |
| Taiho Oncology, INC. | $117.83 | 2023-2025 | |
| Pfizer INC. | $102.24 | 2022-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Comsort, INC | $100.00 | 2019 | |
| Merck Sharp & Dohme LLC | $86.34 | 2022-2025 | Keytruda, Lynparza |
| Gilead Sciences, INC. | $82.80 | 2021-2025 | Trodelvy |
| Lilly USA, LLC | $81.93 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Caris Mpi, INC. | $78.54 | 2025 | Mi Cancer Seek |
| Celgene Corporation | $75.91 | 2019-2024 | Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $69.11 | 2019-2023 | |
| Exelixis INC. | $62.48 | 2024-2025 | Cabometyx |
| Eisai INC. | $59.20 | 2019-2025 | |
| Janssen Biotech, INC. | $59.16 | 2025 | Darzalex, Talvey, Tecvayli |
| Stemline Therapeutics INC. | $57.07 | 2024-2025 | Orserdu |
| Abbvie INC. | $52.84 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $48.19 | 2021-2023 | Yonsa, Odomzo |
| Deciphera Pharmaceuticals INC. | $43.28 | 2024-2025 | Qinlock, Romvimza |
| Array Biopharma INC | $34.94 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Springworks Therapeutics, INC. | $21.05 | 2024 | Ogsiveo |
| Alexion Pharmaceuticals, INC. | $20.08 | 2021 | |
| Tempus Ai, INC | $19.96 | 2025 | Xt Cdx |
| Clovis Oncology, INC. | $18.66 | 2022 | |
| Dova Pharmaceuticals | $18.25 | 2021 | |
| Recordati_rare_diseases_inc. | $17.59 | 2025 | Enjaymo |
| Astellas Pharma US INC | $15.99 | 2024 | Xtandi |
| Sanofi-Aventis U.S. LLC | $15.44 | 2019 | |
| Emd Serono, INC. | $13.99 | 2020 | |
| Csl Behring | $13.11 | 2023 | Idelvion, Afstyla |
| Verastem, INC. | $11.54 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murthy Andavolu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.